•Rivipansel was safe and well-tolerated in sickle cell patients hospitalized for VOC, but did not meet primary or secondary end points.•Rivipansel use early in the course of VOC appeared to shorten length of hospital stay and duration of IV opioid use in post-hoc analyses.